Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BI-3006337

Generic Name: BI-3006337

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Phase 1

Completed

Posted: 2024/03/13

Sponsor:Boehringer Ingelheim

ID:NCT06310005

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Phase 1

Completed

Posted: 2023/08/01

Sponsor:Boehringer Ingelheim

ID:NCT05970640

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Phase 1

Completed

Posted: 2021/10/13

Sponsor:Boehringer Ingelheim

ID:NCT05076422

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Australia's TGA Denies Second Approval Attempt for Eisai's Alzheimer's Drug Leqembi

3 months ago

Australia's Therapeutic Goods Administration (TGA) has rejected Eisai's Alzheimer's treatment Leqembi (lecanemab) for the second time, raising questions about access to novel Alzheimer's therapies in the region.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy